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Abstract
Background—Some chronic pain patients receiving long-term opioid analgesic 
pharmacotherapy are at risk for misusing opioids. Like other addictive behaviors, risk of opioid 
misuse may be signaled by an attentional bias (AB) towards drug-related cues. The purpose of this 
study was to examine opioid AB as a potential predictor of opioid misuse among chronic pain 
patients following behavioral treatment.
Methods—Chronic pain patients taking long-term opioid analgesics (N = 47) completed a dot 
probe task designed to assess opioid AB, as well as self-report measures of opioid misuse and pain 
severity, and then participated in behavioral treatment. Regression analyses examined opioid AB 
and cue-elicited craving as predictors of opioid misuse at 3-months posttreatment follow-up.
Results—Patients who scored high on a measure of opioid misuse risk following treatment 
exhibited significantly greater opioid AB scores than patients at low risk for opioid misuse. Opioid 
AB for 200 ms cues and cue-elicited craving significantly predicted opioid misuse risk 20 weeks 
later, even after controlling for pre-treatment opioid dependence diagnosis, opioid misuse, and 
pain severity (Model R2 = .50).
Conclusion—Biased initial attentional orienting to prescription opioid cues and cue-elicited 
craving may reliably signal future opioid misuse risk following treatment. These measures may 
therefore provide potential prognostic indicators of treatment outcome.
*Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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1. INTRODUCTION
Chronic pain conditions are commonly treated with prescription opioids, which may relieve 
pain by targeting the descending pain modulatory system (Besson, 1999), decreasing 
somatosensory and thalamic activation (Wagner et al., 2007; Wise et al., 2002), modifying 
amygdala function (Oertel et al., 2007), and altering neurotransmission in spinal dorsal horn 
(Le Bars et al., 1980; Yaksh, 1985, 1981). In addition to analgesia, opioid administration 
stimulates dopamine release from the ventral tegmental area to the nucleus accumbens, 
facilitating opioid-related reinforcement learning (Shippenberg et al., 1993). Through this 
mechanism, opioids and opioid-related cues are imbued with incentive salience and come to 
signal pain relief and reward (Becker et al., 2012; Robinson and Berridge, 2001). Opioid-
induced reward learning may be one key process underpinning the transition from medically 
authorized opioid use to opioid misuse and addiction (Garland et al., 2013a).
While a majority of chronic pain patients take opioids as prescribed, a substantial subset of 
patients are at risk for escalating from appropriate opioid use to misuse. A systematic review 
concluded that 11.5% of chronic pain patients evidenced signs of opioid misuse including 
self-medication of negative affect with opioids and unauthorized dose escalation (Fishbain et 
al., 2007). It is important to ascertain which patients are at risk for opioid misuse. Yet, these 
determinations are difficult because many chronic pain patients seek opioids for pain relief. 
Inadequately treated pain and physiological tolerance can result in opioid-seeking behaviors 
and opioid dose escalation – a pattern termed pseudoaddiction (Wilson, 2007). Fear of being 
stigmatized, legally penalized, or deprived of medication by health care providers may lead 
some patients to conceal opioid misuse. As such, cognitive tasks that do not rely on patient 
self-report may be useful in identifying individuals at risk for opioid misuse.
Cognitive tasks may have prognostic value in detection and prediction of opioid misuse risk 
because misuse of opioids, like other addictive behaviors, may involve automatic cognitive 
processes that organize and drive compulsive drug taking (Stacy and Wiers, 2010). 
Recurrent substance use establishes automatic drug-use action schemas that compel 
consumption of the substance through automatized sequences of stimulus-bound, context-
dependent behavior, including the biasing of attention towards substance-relevant stimuli 
(Pierce and Vanderschuren, 2010; Tiffany, 1990). Insofar as cues associated with past drug 
use are motivationally salient for habitual drug users, they capture attention, which amplifies 
their motivational salience (Franken, 2003). This phenomenon--addiction attentional bias 
(AB)--is evidenced on dot probe tasks by shorter reaction times (RT) to probes replacing 
drug-related images relative to probes replacing neutral images (Field and Cox, 2008). 
Addiction AB is associated with craving (Field et al., 2009) and has been reported to predict 
relapse following addiction treatment (e.g., Cox et al., 2002; Garland et al., 2012a).
AB toward heroin-related stimuli has been observed among heroin dependent individuals 
performing dot probe tasks (Constantinou et al., 2010; Lubman et al., 2000; Marissen et al., 
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2006). Recently, our lab reported the first evidence of an AB toward prescription opioids 
(i.e., opioid AB) among chronic pain patients meeting criteria for opioid dependence 
(Garland et al., 2013b). In this study, opioid-dependent chronic pain patients exhibited 
significantly greater opioid AB than chronic pain patients who used, but were not dependent 
on, opioids. In addition, opioid AB was significantly positively correlated with opioid 
craving. Although this study established the presence of an opioid AB, it is not known 
whether opioid AB predicts future opioid misuse. Hence, the purpose of the present study 
was to examine opioid AB as a potential predictor of opioid misuse among chronic pain 
patients. We hypothesized that patients with higher levels of opioid AB at initial evaluation 
would evidence greater risk for future opioid misuse than patients with low levels of opioid 
AB, even after controlling for other factors including initial levels of opioid misuse risk, 
pain severity, and opioid dependence diagnosis. Because exposure to opioid cues might 
elicit craving responses in addition to attentional responses, we also examined cue-elicited 
craving as a predictor of future opioid misuse risk.
2. METHODS
Data for this study were drawn from a randomized controlled trial that compared the 
efficacy of an eight-week long mindfulness-based treatment, Mindfulness-Oriented 
Recovery Enhancement (MORE), to that of a support group (SG) control condition (random 
allocation ratio 1:1) vis-a-vis reduction of chronic pain and opioid misuse (Garland et al., 
2014b). Participants were recruited from primary care, pain, and neurology clinics, reported 
recurrent pain on more days than not stemming from chronic non-cancer-related pain 
conditions, and had taken opioid analgesics daily or nearly every day for at least the past 90 
days (Chou et al., 2009). At pretreatment, participants completed self-report measures of 
pain severity and the Current Opioid Misuse Measure (COMM; Butler et al., 2007), and a 
dot probe task designed to measure opioid AB. At a 3-month posttreatment follow-up, 
participants completed the COMM again. Participants with full opioid AB and opioid 
misuse data (N = 47; 64% female; aged 48±13 years) were included in the present study. 
The study protocol was approved by the Florida State University Institutional Review 
Board, and all procedures complied with the 1975 Helsinki Declaration. Subjects provided 
informed consent for their participation.
Participants were assessed for prescription opioid dependence with the Mini-International 
Neuropsychiatric Interview 6.0 (MINI; Sheehan et al., 1998), and were excluded if suicidal 
or psychotic. Although all participants reported symptoms of physiological dependence (i.e., 
tolerance and withdrawal) on the MINI resulting from prolonged use of opioids, a smaller 
percentage (30%) met DSM-IV opioid use disorder criteria. However, most (73%) 
participants reported opioid analgesic misuse at pretreatment as defined by a validated cut-
point on the COMM (Meltzer et al., 2011). A number of subjects met diagnostic criteria for 
comorbid major depression (61%) and/or generalized anxiety disorder (30%). Participants 
were paid $200 for study participation.
2.1. Measures
2.1.1 Dot probe task—A dot probe task was used to measure opioid AB. This task was 
generated in E-Prime 2.0 (PST Inc., Pittsburgh, PA) and presented on 15″ computer monitor. 
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Each trial began with a fixation cross presented for 500 ms. Next, two images matched for 
visual complexity, composition, and figure-ground relationships appeared side by side on 
the screen. On critical trials, pairs of photos containing one opioid-related image and one 
neutral image were presented for either 200 or 2000 ms. On filler trials, pairs of neutral 
photos were presented. The set of 12 opioid images represented commonly prescribed 
opioids in a number of forms, including photos of pills (e.g., Oxycontin), pill bottles, and 
powdered opioids for insufflation. Neutral images included 12 photos culled from the 
International Affective Picture System (Lang et al., 1997) depicting household items (e.g., 
napkin, pencil). Presentation duration and left/right position of the images were randomized 
and counterbalanced across 12 filler trials and 64 critical trials. A target probe (one dot) 
replaced one of the images after a 50 ms inter-stimulus interval (ISI). Probes appeared for 
100 ms and their locations were counterbalanced. Participants indicated probe location via a 
button press on a keypad.
2.1.2 Cue-elicited craving—Immediately before and after the opioid dot probe task 
participants were asked “How much do you want your opioids right now?” anchored on a 
10-point scale (1 = not at all, 10 = extremely). The difference of these ratings was used to 
index cue-elicited craving.
2.1.3 Opioid misuse risk—The Current Opioid Misuse Measure (COMM; α = .83; 
Butler et al., 2007) assessed aberrant drug-related behavior. Participants responded to 17 
items rated on a Likert scale (0 = never, 4 = very often) regarding how often in the past 30 
days they had engaged in behaviors potentially reflective of opioid misuse or took opioid 
medication in excessive doses or in nonprescribed ways. A validated cut-point of 13 was 
used to establish whether or not a participant could be classified at high risk for opioid 
misuse (Meltzer et al., 2011).
2.1.4 Pain severity—Pain severity was measured with the 4-item Pain Severity subscale 
of the Brief Pain Inventory (BPI; α = .87) widely used to assess chronic pain (Cleeland, 
1994). Response options ranged from 0 (no pain) to 10 (pain as bad as I can imagine).
2.2. Data Analysis
With regard to the analysis of participant AB data, trials with extreme RTs, defined as those 
with RTs ±3 SDs beyond the individual mean RT (Field et al., 2004; Ratcliffe, 1993), were 
eliminated as outliers (< 2%). Trials on which the probe location was incorrectly identified 
(13%) were also omitted (Townshend and Duka, 2007). AB scores were calculated by 
subtracting participant’s mean RT to probes replacing opioid photos from their mean RT to 
probes replacing neutral photos, such that positive scores indicate an AB toward opioid cues 
(Field et al., 2004). AB scores were approximately normally distributed (Kolmogorov-
Smirnov p’s > .10).
Hierarchical linear regression analyzed to what extent pretreatment opioid AB scores and 
cue-elicited craving predicted opioid misuse at 3-months posttreatment, after controlling for 
treatment condition (MORE vs. SG) and pretreatment opioid dependence diagnosis, opioid 
misuse, and pain severity. Collinearity diagnostics were assessed and no predictor variables 
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exceeded recommended tolerance (< 0.2) and variance inflation factor thresholds (> 5.0). 
Stepwise and logistic regression analyses were used for sensitivity analyses.
3. RESULTS
3.1 Between-groups differences in opioid AB
In unadjusted analyses, individuals exceeding the validated cut-point on the COMM for high 
risk of opioid misuse at 3-months follow-up had significantly higher 200 ms (t = 2.15, p = .
035, d = .66) and 2000 ms opioid AB scores (t = 2.16, p = .037, d = .68) at pretreatment than 
individuals scoring beneath the cut-point on the COMM (see Figure 1). Within-group one-
sample t-tests revealed that those exceeding the cut-point on the COMM at 3-months follow-
up had significantly nonzero mean 200 ms opioid AB (t = 2.69, p = .012), but did not have 
significantly nonzero mean 2000 ms opioid AB (t = 1.63, p = .11). For individuals scoring 
beneath the cut-point on the COMM at follow-up, 2000 ms AB (t = 1.88, p = .07) and 200 
ms opioid AB (t = −.32, p = .75) scores were not significantly different than zero. Because 
the 2000 ms opioid AB was not significantly different than zero for either group, this 
variable was not included in subsequent regression analyses.
3.2 Prediction of future opioid misuse following treatment
In step 1, pretreatment COMM scores explained a significant portion of variance in COMM 
scores at 3-months follow-up, irrespective of treatment condition, pre-treatment pain 
severity, and presence of opioid dependence diagnosis. In step 2, adding cue-elicited craving 
and 200 ms opioid AB scores to the model significantly predicted future COMM scores and 
contributed a significant increase in Model R2. The full model predicted 50% of the variance 
in COMM scores at 3-month follow-up (see Table 1). In supplementary analyses1, we 
conducted a stepwise regression with removal. Model results did not differ substantively in 
terms of valence or statistical significance from the hierarchical regression described above: 
baseline opioid misuse, pain severity, cue-elicited craving, and 200 ms opioid AB were 
retained in the final stepwise model. Logistic regression analysis predicting whether or not 
participants exceeded the opioid misuse threshold on the COMM at 3-month follow-up 
found this final set of variables to correctly classify 89.3% of cases.
4. DISCUSSION
Findings from this study of chronic pain patients treated for comorbid pain and prescription 
opioid misuse suggest that attentional and subjective reactivity to opioid cues prior to 
behavioral treatment may signal future risk of opioid misuse. Consistent with our 
hypotheses, above and beyond the predictive power of pre-treatment levels of opioid misuse 
risk, pain severity, and prescription opioid dependence, 200 ms opioid AB scores and cue-
elicited craving significantly and independently predicted risk of opioid misuse more than 
20 weeks later. To our knowledge, this is the first study to demonstrate that AB to 
prescription opioids prospectively predicts opioid misuse following treatment. The 
combined predictive power of opioid AB and cue-elicited craving (which together explained 
1Supplementary material can be found by accessing the online version of this paper at http://dx.doi.org and by entering doi:...
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17% of the variance in opioid misuse risk at 3-months posttreatment) indicates that these 
factors may be markers of the proclivity to engage in opioid misuse.
In unadjusted analyses, individuals at elevated risk for opioid misuse at 3-months 
posttreatment follow-up exhibited a significant mean AB toward opioid cues presented for 
200 ms, whereas those at low risk for opioid misuse had a nonsignificant bias away from 
opioid cues presented for 2000 ms (possibly indicating attentional avoidance of drug stimuli; 
e.g., Garland et al., 2012b). In individual difference analyses adjusted for clinically relevant 
covariates, 200 ms AB scores significantly predicted future opioid misuse risk. The 200 ms 
AB is theorized to index automatic, initial orienting toward drug cues, whereas AB for 
longer duration stimuli (ranging from 500 – 2000 ms) is theorized to index higher-order 
attentional processes, such as delayed disengagement of attention from drug-related cues 
(Field and Cox, 2008). Thus, it appears as if opioid misusers exhibit initial attentional 
orienting toward opioid cues prior to treatment and this attentional orienting independently 
predicts the tendency to engage in opioid misuse in multivariate analyses controlling for 
factors like pre-treatment opioid misuse, prescription opioid dependence diagnosis, and 
chronic pain severity. Furthermore, heightened cue-elicited craving during the dot probe task 
predicted future opioid misuse risk, indicating that individuals who experienced the largest 
increases in craving following exposure to opioid cues were most at-risk to misuse opioids 
20 weeks later.
This study was limited by the lack of a quantitative measure of opioid dosing and adjuvant 
psychiatric medication use. Future studies should carefully assess opioid misuse by tracking 
opioid dosing via prescription history, pill count, and toxicology screens, as well as through 
clinician-rated opioid misuse assessment and legal history. Despite these limitations, study 
findings suggest that behavioral and self-reported indices of opioid reactivity may reliably 
signal future opioid misuse risk following treatment, and therefore provide potential 
prognostic indicators of treatment outcome. Interventions that target opioid AB and cue-
reactivity hold promise for the treatment of opioid misuse among chronic pain patients 
(Garland et al., 2014a).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
Role of the Funding Source: This work was supported by grant numbers DA032517 and DA037005 from the 
National Institutes of Health awarded to ELG.; and a grant from the Fahs Beck Fund for Research and 
Experimentation, also awarded to ELG. NIDA and the Fahs Beck Fund had no further role in study design; in the 
collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for 
publication.
References
Becker S, Gandhi W, Schweinhardt P. Cerebral interactions of pain and reward and their relevance for 
chronic pain. Neurosci Lett. 2012; 520:182–187. [PubMed: 22440855] 
Besson JM. The neurobiology of pain. Lancet. 1999; 353:1610–1615. [PubMed: 10334274] 
Garland and Howard Page 6






















Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, Jamison RN. Development and 
validation of the Current Opioid Misuse Measure. Pain. 2007; 130:144–156. [PubMed: 17493754] 
Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley 
KM, Fudin J, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer 
pain. J Pain. 2009; 10:113–130. [PubMed: 19187889] 
Cleeland, CS. Brief Pain Inventory–Short Form (BPI–SF). MD Anderson Cancer Center; Houston, 
TX: 1994. 
Constantinou N, Morgan CJ, Battistella S, O’Ryan D, Davis P, Curran HV. Attentional bias, inhibitory 
control and acute stress in current and former opiate addicts. Drug Alcohol Depend. 2010; 109:220–
225. [PubMed: 20172662] 
Cox WM, Hogan LM, Kristian MR, Race JH. Alcohol attentional bias as a predictor of alcohol 
abusers’ treatment outcome. Drug Alcohol Depend. 2002; 68:237–243. [PubMed: 12393218] 
Field M, Cox WM. Attentional bias in addictive behaviors: a review of its development, causes, and 
consequences. Drug Alcohol Depend. 2008; 97:1–20. [PubMed: 18479844] 
Field M, Mogg K, Zetteler J, Bradley BP. Attentional biases for alcohol cues in heavy and light social 
drinkers: the roles of initial orienting and maintained attention. Psychopharmacology (Berl). 2004; 
176:88–93. [PubMed: 15071718] 
Field M, Munafo MR, Franken IH. A meta-analytic investigation of the relationship between 
attentional bias and subjective craving in substance abuse. Psychol Bull. 2009; 135:589–607. 
[PubMed: 19586163] 
Fishbain DA, Cole B, Lewis J, Rosomoff HL, Rosomoff RS. What percentage of chronic 
nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction 
and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Med. 2007; 
9:444–459. [PubMed: 18489635] 
Franken IH. Drug craving and addiction: integrating psychological and neuropsychopharmacological 
approaches. Prog Neuropsychopharmacol Biol Psychiatry. 2003; 27:563–579. [PubMed: 
12787841] 
Garland EL, Franken IH, Howard MO. Cue-elicited heart rate variability and attentional bias predict 
alcohol relapse following treatment. Psychopharmacology (Berl). 2012a; 222:17–26. [PubMed: 
22203318] 
Garland EL, Franken IH, Sheetz JJ, Howard MO. Alcohol attentional bias is associated with 
autonomic indices of stress-primed alcohol cue-reactivity in alcohol-dependent patients. Exp Clin 
Psychopharmacol. 2012b; 20:225–235. [PubMed: 22329555] 
Garland EL, Froeliger B, Howard MO. Effects of Mindfulness-Oriented Recovery Enhancement on 
reward responsiveness and opioid cue-reactivity. Psychopharmacology (Berl). 2014a; 231:3229–
3238. [PubMed: 24595503] 
Garland EL, Froeliger B, Zeidan F, Partin K, Howard MO. The downward spiral of chronic pain, 
prescription opioid misuse, and addiction: cognitive, affective, and neuropsychopharmacologic 
pathways. Neurosci Biobehav Rev. 2013a; 37:2597–2607. [PubMed: 23988582] 
Garland EL, Froeliger BE, Passik SD, Howard MO. Attentional bias for prescription opioid cues 
among opioid dependent chronic pain patients. J Behav Med. 2013b; 36:611–620. [PubMed: 
22968666] 
Garland EL, Manusov EG, Froeliger B, Kelly A, Williams JM, Howard MO. Mindfulness-oriented 
recovery enhancement for chronic pain and prescription opioid misuse: results from an early-stage 
randomized controlled trial. J Consult Clin Psychol. 2014b; 82:448–459. [PubMed: 24491075] 
Lang, P.; Bradley, M.; Cuthbert, B. NIMH Center for the Study of Emotion and Attention. University 
of Florida; 1997. International Affective Picture System (IAPS): Technical Manual And Affective 
Ratings. 
Le Bars D, Guilbaud G, Chitour D, Besson JM. Does systemic morphine increase descending 
inhibitory controls of dorsal horn neurones involved in nociception? Brain Res. 1980; 202:223–
228. [PubMed: 6253026] 
Lubman DI, Peters LA, Mogg K, Bradley BP, Deakin JF. Attentional bias for drug cues in opiate 
dependence. Psychol Med. 2000; 30:169–75. [PubMed: 10722187] 
Garland and Howard Page 7






















Marissen MA, Franken IH, Waters AJ, Blanken P, van den Brink W, Hendriks VM. Attentional bias 
predicts heroin relapse following treatment. Addiction. 2006; 101:1306–1312. [PubMed: 
16911730] 
Meltzer EC, Rybin D, Saitz R, Samet JH, Schwartz SL, Butler SF, Liebschutz JM. Identifying 
prescription opioid use disorder in primary care: diagnostic characteristics of the Current Opioid 
Misuse Measure (COMM). Pain. 2011; 152:397–402. [PubMed: 21177035] 
Oertel BG, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, Lanfermann H, Lötsch J. 
Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther. 
2007; 83:577–588. [PubMed: 18030306] 
Pierce RC, Vanderschuren L. Kicking the habit: The neural basis of ingrained behaviors in cocaine 
addiction. Neurosci Biobehav Rev. 2010; 35:212–219. [PubMed: 20097224] 
Ratcliffe R. Methods of dealing with reaction-time outliers. Psychol Bull. 1993; 114:510–532. 
[PubMed: 8272468] 
Robinson TE, Berridge KC. Incentive-sensitization and addiction. Addiction. 2001; 96:103–14. 
[PubMed: 11177523] 
Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar 
GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation 
of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998; 
59(Suppl 20):22–33. quiz 34–57. [PubMed: 9881538] 
Shippenberg TS, Bals-Kubik R, Herz A. Examination of the neurochemical substrates mediating the 
motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs. D-2 
dopamine receptors. J Pharmacol Exp Ther. 1993; 265:53–59. [PubMed: 8386244] 
Stacy AW, Wiers RW. Implicit cognition and addiction: a tool for explaining paradoxical behavior. 
Ann Rev Clin Psychol. 2010; 6:551–575. [PubMed: 20192786] 
Tiffany ST. A cognitive model of drug urges and drug-use behavior: role of automatic and 
nonautomatic processes. Psychol Rev. 1990; 97:147–168. [PubMed: 2186423] 
Townshend JM, Duka T. Avoidance of alcohol-related stimuli in alcohol-dependent inpatients. 
Alcohol Clin Exp Res. 2007; 31:1349–1357. [PubMed: 17550367] 
Wagner KJ, Sprenger T, Kochs EF, Tölle TR, Valet M, Willoch F. Imaging human cerebral pain 
modulation by dose-dependent opioid analgesia: a positron emission tomography activation study 
using remifentanil. Anesthesiology. 2007; 106:548–556. [PubMed: 17325514] 
Wilson JF. Strategies to stop abuse of prescribed opioid drugs. Ann Intern Med. 2007; 146:897–900. 
[PubMed: 17577013] 
Wise RG, Rogers R, Painter D, Bantick S, Ploghaus A, Williams P, Rapeport G, Tracey I, et al. 
Combining fMRI with a pharmacokinetic model to determine which brain areas activated by 
painful stimulation are specifically modulated by remifentanil. Neuroimage. 2002; 16:999. 
[PubMed: 12202088] 
Yaksh TL. Spinal opiate analgesia: characteristics and principles of action. Pain. 1981; 11:293–346. 
[PubMed: 6276842] 
Yaksh TL. Pharmacology of spinal adrenergic systems which modulate spinal nociceptive processing. 
Pharmacol Biochem Behav. 1985; 22:845–858. [PubMed: 2861606] 
Garland and Howard Page 8






















• Opioid dependent pain patients exhibit an attentional bias toward opioid cues
• Opioid attentional bias predicted opioid misuse 20 weeks later
• Cue-elicited craving predicted opioid misuse 20 weeks later
• Attentional bias and cue-elicited craving may signal opioid misuse risk
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Between-groups differences in pre-treatment opioid attentional bias scores (higher number = 
greater AB) for patients with elevated opioid misuse risk (n = 28) and low risk for opioid 
misuse (n = 19) 3 months following completion of behavioral treatment for chronic pain and 
opioid misuse. Error bars indicate ±1 standard error of measurement.
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Table 1
Predictors of opioid misuse risk at 3-months posttreatment for a sample of chronic patient patients completing 
behavioral treatments.
Variable
Step 1 Step 2
β β
Step 1
 Treatment conditiona .09 .14
 Pre-treatment opioid misuse .48** .49**
 Pre-treatment pain severity .25 .26*
 Opioid dependence dx −.14 −.26
Step 2
 Cue-elicited craving - .32**












Treatment condition was a dichotomous variable representing the treatment to which subjects were randomly allocated in the parent RCT from 
which the present data were derived (Garland et al., 2014). Treatment condition did not significantly predict opioid misuse at 3-months follow-up.
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